Abstract:Abstract BackgroundEsophageal cancer remains a dominating cause of cancer-associated death and has shown a sharp increase of more than 6-fold increase rates all over the world. It is divided into two main pathological types: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Most of the patients are diagnosed at the advanced stage with distant metastasis and poor prognosis. Thus, it is urgent for us to identify new more effective drugs to improve the prognosis of patients with esophageal cancer. Elaiophylin is a novel autophagy inhibitor at the late stage, which is a C2 symmetric macrolides separated from Streptomyces Niger. It was proved to have anti-tumor ability of various of cancers, yet little is known whether it could inhibit the progression of esophageal squamous cancer. The study is aimed to explore the effect of Elaiophylin on ESCC. MethodsThe protein expression level was detected by western blot assay. The viability of ESCC cells was detected by CCK8 assay. The proliferation rate was measured by ki67 immunofluorescent staining. The migratory ability of ESCC cells was identified by transwell assay. The apoptosis rate of ESCC cells was explored by Annexin V/PI analysis. And the genes might be regulated by Elaiophylin was analyzed by RNA-seq assay and verified by RT-qPCR assay. The experiments in vivo were conducted by subcutaneous into tumor in BALB/C-Nu mice. ResultsIn the study, we firstly found that the Elaiophylin was a novel autophagy inhibitor in ESCC cells which is consistent with the previous studies. In addition, Elaiophylin can inhibit the proliferation and migration of ESCCs, and accelerate its apoptosis. And the activity of PI3K/AKT pathway was inhibited by Elaiophylin, the mRNA and protein expression level of EIF4B was both downregulated by Elaiophylin. Mechanistically, silencing of EIF4B could inhibit the proliferation and migration of ESCC cells and promoted apoptosis, which could be rescued by EIF4B-OE. Moreover, EIF4B overexpression suppressed the apoptosis, while increased the proliferation and migration of ESCC cells which resulted from Elaiophylin. Finally, Elaiophylin could inhibit the proliferation of esophageal cancer in vivo compared to the control group. ConclusionsTogether, our results indicated that Elaiophylin is a novel autophagy inhibitor governing growth and migratory ability of ESCC cells through PI3K/AKT signaling pathway and inhibit the proliferation of esophageal tumor in vivo. simultaneously, and identified EIF4B as a target of Elaiophylin, which might provide a new therapeutic strategy for esophageal squamous cell carcinoma.

Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo

Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway

Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway

Ixazomib Induces Apoptosis and Suppresses Proliferation in Esophageal Squamous Cell Carcinoma through Activation of the c-Myc/NOXA Pathway

Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways

Isofraxidin Inhibited Proliferation and Induced Apoptosis Via Blockage of Akt Pathway in Human Colorectal Cancer Cells

Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cell Carcinoma via the PI3K/AKT Signaling Pathway

Cloperastine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by suppressing mitochondrial oxidative phosphorylation

A Review: PI3K/AKT/mTOR Signaling Pathway and Its Regulated Eukaryotic Translation Initiation Factors May Be a Potential Therapeutic Target in Esophageal Squamous Cell Carcinoma

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Apatinib Inhibits Tumor Progression and Promotes Antitumor Efficacy of Cytotoxic Drugs in Esophageal Squamous Cell Carcinoma.

CDK4/6 Inhibitor-Shr6390 Exerts Potent Antitumor Activity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylated Rb and Inducing G1 Cell Cycle Arrest

Mir-671-5p Blocks the Progression of Human Esophageal Squamous Cell Carcinoma by Suppressing FGFR2

Oxethazaine inhibits esophageal squamous cell carcinoma proliferation and metastasis by targeting aurora kinase A

Targeting leucine-rich PPR motif-containing protein/LRPPRC by 5,7,4′-trimethoxyflavone suppresses esophageal squamous cell carcinoma progression

Stable knockdown of Aurora-A by vector-based RNA interference in human esophageal squamous cell carcinoma cell line inhibits tumor cell proliferation, invasion and enhances apoptosis.

Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma

Targeting PFKL with Penfluridol Inhibits Glycolysis and Suppresses Esophageal Cancer Tumorigenesis in an AMPK/FOXO3a/BIM-dependent Manner.

Ricolinostat (ACY-1215) Suppresses Proliferation and Promotes Apoptosis in Esophageal Squamous Cell Carcinoma Via Mir-30D/pi3k/akt/mtor and ERK Pathways

Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo